A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhoea Predominant Irritable Bowel Syndrome (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs ASP 7147 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Seldar Pharma
- 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 13 Dec 2013 Planned number of patients changed from 75 to 60 as reported by ClinicalTrials.gov.